BTI-320

N/A

Report date: 2024/08/30 20:00:41
NME

Base Information

Drug NameBTI-320
Drug Alias NamePAZ-320BTI-320
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSalivary alpha-amylase inhibitorsMaltase-glucoamylase inhibitorsPeptide hydrolase inhibitors
TargetsMaltase-glucoamylasePeptide hydrolaseSalivary alpha-amylase
Therapy Area/IndicationsPrediabetic StateDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceHong Kong
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of BuffaloBoston Therapeutics IncAdvance Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChinese University Of Hong Kong (Cuhk)Boston Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsPrediabetic StateDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A